How much funding has Bicara Therapeutics raised?

Bicara Therapeutics has raised $313.0M in total funding, most recently a Series C round.

Who are Bicara Therapeutics's investors?

Bicara Therapeutics's investors include Red Tree Venture Capital, TPG (Growth/Rise), Biocon Limited, F-Prime Capital, Eight Roads Ventures, Deerfield Management.

When was Bicara Therapeutics founded?

Bicara Therapeutics was founded in 2020.

Where is Bicara Therapeutics headquartered?

Bicara Therapeutics is headquartered in Cambridge, Massachusetts, United States.

What industry is Bicara Therapeutics in?

Bicara Therapeutics operates in Biotech, Healthcare, Therapeutics.

How many employees does Bicara Therapeutics have?

Bicara Therapeutics has 51-200 employees.

Bicara Therapeutics

IPO

Fighting cancer with precision and power.

Public · Cambridge, United States · Founded 2020 · $313.0M raised

Biotech

Healthcare

Therapeutics

Headquarters: Cambridge, Massachusetts
Employees: 51–200
Founded: 2020
Business Model: B2B
Website: bicaratherapeutics.com

Total Funding: $313.0M
Last Round: $165.0M Series CDec 2023
Rounds: 3
Type: Public

About

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class bifunctional biologics that combine tumor-targeting antibodies with tumor microenvironment modulators to treat solid tumors. Its bifunctional antibody platform is designed to deliver immunomodulatory payloads directly to the tumor site, enabling synergistic anti-tumor immune activity. The company is publicly traded (Nasdaq: BCAX) and advancing its lead programs through Phase 1b and Phase 3 clinical trials.

Summary

Bicara Therapeutics is a Biotech company based in Cambridge, United States, founded in 2020. It has raised $313.0M in total across 3 rounds, most recently a $165.0M Series C round in Dec 2023. Investors include Red Tree Venture Capital, TPG (Growth/Rise) and Biocon Limited.

LinkedIn X (Twitter)